MedDataX Logo

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT ID: NCT07217015

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-24

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

STAT6 stat6 degrader targeted protein degrader Phase 2 Phase 2b kt-621

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: KT-621 Dose 1

Group Type EXPERIMENTAL

KT-621

Intervention Type DRUG

Oral drug

Group 2: KT-621 Dose 2

Group Type EXPERIMENTAL

KT-621

Intervention Type DRUG

Oral drug

Group 3: KT-621 Dose 3

Group Type EXPERIMENTAL

KT-621

Intervention Type DRUG

Oral drug

Group 4: Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Oral placebo matched to KT-621

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KT-621

Oral drug

Intervention Type DRUG

Placebo

Oral placebo matched to KT-621

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be 18 years (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.
* Must have chronic AD that has been present for at least 3 years before the Screening visit.
* Must have an EASI score ≥ 16 at the Screening and Baseline visits.
* Must have a vIGA-AD score ≥ 3 (scale of 0 to 4) at the Screening and Baseline visits.
* Must have at least 10% BSA of AD involvement at the Screening and Baseline visits.
* Must have a weekly average Peak Pruritus NRS value ≥ 4 at the Baseline visit.
* Must have a documented history within the 6 months prior to the Baseline visit of either an inadequate response to, or inability to take, topical medications for the treatment of AD.
* Must apply a stable dose of moisturizer at least twice daily for at least 7 consecutive days immediately prior to the Baseline visit. Participants should be willing to continue using moisturizer twice daily during the study.
* Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
* Must agree to contraceptive requirements in compliance with the clinical study and local requirements.

Exclusion Criteria

* Must not have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the Investigator in the 4 weeks before the baseline visit.
* Must not have other skin conditions, such as contact dermatitis, psoriasis, tinea corporis, or lupus erythematosus, that may interfere with study assessments.
* Must not have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases or disorders.
* Must not have any surgical or medical procedure planned during participation in the study.
* Must not have a history of alcohol or substance abuse within the previous 2 years.
* Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
* Must not have a history of lack of response to any medication targeting interleukin (IL)-4, IL-13, and/or janus kinase (JAK)- signal transducer and activator of transcription (STAT) pathways (e.g. dupilumab, tralokinumab, upadacitinib, abrocitinib) at approved doses after at least 16 weeks of therapy.
* Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
* Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
* Female participants of childbearing potential must not have a positive or undetermined pregnancy result at the Screening and baseline visits.
* Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
* Must not be taking or have taken any prespecified prohibited therapies within a specific timeframe as evaluated by the Investigator.
* Must not have a known sensitivity to any of the components of KT-621.
* Must not be a member of the investigational team or his/her immediate family.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kymera Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kymera Investigative Site

Birmingham, Alabama, United States

Site Status RECRUITING

Kymera Investigative Site

North Little Rock, Arkansas, United States

Site Status RECRUITING

Kymera Investigative Site

Los Angeles, California, United States

Site Status RECRUITING

Kymera Investigative Site

Delray Beach, Florida, United States

Site Status RECRUITING

Kymera Investigative Site

Miami, Florida, United States

Site Status RECRUITING

Kymera Investigative Site

Miramar, Florida, United States

Site Status RECRUITING

Kymera Investigative Site

Ann Arbor, Michigan, United States

Site Status RECRUITING

Kymera Investigative Site

Fargo, North Dakota, United States

Site Status RECRUITING

Kymera Investigative Site

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Kymera Investigative Site

San Antonio, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kymera Medical Director

Role: CONTACT

Phone: 857-285-5300

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-522370-36-00

Identifier Type: CTIS

Identifier Source: secondary_id

KT621-AD-201

Identifier Type: -

Identifier Source: org_study_id